APIE, based in Research Triangle Park, is now raising a Series A round of funding. The company has hired an investment banker and recently scored a win by adding life sciences industry heavyweight Jim Greenwood to its board. Greenwood is known in biopharma for his 18-year tenure as president and CEO of BIO, the world’s largest biotech industry organization.
Read More
APIE’s mission is to develop and commercialize novel Apelin Receptor biased agonist drug therapies.
Read More
A newly established high-powered Research Triangle Park company, APIE Therapeutics, has signed a licensing agreement with RTI International to develop a class of RTI-developed compounds targeting heart failure and lung disease. Here’s the story.
Read More
An agreement with RTI advances RTP-based APIE Therapeutics’ pursuit of a treatment for idiopathic pulmonary fibrosis, a rare lung disease.
Read More
